Read Time:12 Second
The stock of Danish biotech Novo Nordisk was down 1.7% premarket Tuesday, after a study found that the company’s obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.’s Mounjaro, in speed and magnitude of weight loss.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
